Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. This work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy – Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts. Clinical trial registration: NCT02227251 (ClinicalTrials.gov)

Authors

Publication Details

Journal
Figshare
Published
2026-11-12
DOI
https://doi.org/10.6084/m9.figshare.34998583
Primary Topic
Health Systems, Economic Evaluations, Quality of Life
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma

Brian Thomas Hill, Nagesh Kalakonda, Sylvain Choquet, Krzysztof Warzocha et al.
Figshare
Health Systems, Economic Evaluations, Quality of Life
article

Health-Related Quality of Life and Utility Outcomes with Selinexor in Relapsed/refractory Diffuse Large B-Cell Lymphoma

Brian Thomas Hill, Nagesh Kalakonda, Sylvain Choquet, Krzysztof Warzocha, D. Tomaras, Patrick Daniele, Catherine Thiéblemont, Ronit Gurion, Sharon Shacham, Joost S.P. Vermaat, Matthew Ku, Nada Hamad, Andre Henri Goy, Gabriel Tremblay, Ágnes Nagy, Éric Van Den Neste, Michael Kauffman, Miguel Ángel Canales Albendea, George Follows, Fritz Offner, Michael Schuster, FEDERICA CAVALLO, John Kuruvilla, Ulrich Jäger, Theodoros P Vasilakopoulos, Sameer Bakhshi, Jatin Shah, Marie Maerevoet, Reda Bouabdallah, Josee Zijlstra, Priyanka Samal, Juan Manuel Sancho, Miklós Egyed, Paolo Caimi, Rene-Olivier Casasnovas, Fátima de la Cruz
article en

Abstract

Aim: Evaluate health-related quality of life (HRQoL) and health utility impact of single-agent selinexor in heavily pretreated patients with relapsed/refractory diffuse large B-cell lymphoma. Patients & methods: Functional Assessment of Cancer Therapy (FACT) – Lymphoma and EuroQoL five-dimensions five-levels data collected in the single-arm Phase IIb trial SADAL (NCT02227251) were analyzed with mixed-effects models. Results: Treatment responders maintained higher FACT – Lymphoma (p ≤ 0.05), FACT – General (p < 0.05) and EuroQoL five-dimensions five-levels index scores (p < 0.001) beginning in cycle 3. The estimated difference in health state utilities for treatment response and progressive disease was both statistically significant and clinically meaningful (mean difference: 0.07; p = 0.001). Conclusion: In patients with relapsed/refractory diffuse large B-cell lymphoma, objective response to selinexor was associated with HRQoL maintenance, reduction in disease-related HRQoL decrements and higher health utilities. This work examined quality of life (QoL) among patients with relapsed/refractory diffuse large B-cell lymphoma with two to five prior therapies who received single-agent selinexor in the SADAL clinical trial. Analysis of patient-reported Functional Assessment of Cancer Therapy – Lymphoma and EuroQoL five-dimensions five-levels data showed that patients who had objective clinical response to selinexor maintained their QoL over the course of treatment. Grade ≥3 adverse events and serious adverse events were not associated with clinically meaningful negative QoL impacts. Clinical trial registration: NCT02227251 (ClinicalTrials.gov)

Figshare
Good health and well-being
Health Systems, Economic Evaluations, Quality of Life
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon